Scoop: Gilead ter­mi­nates ear­ly-stage FLT3 tri­al in sol­id tu­mors

Gilead chopped a Phase Ib dose es­ca­la­tion study in re­cent days, with an up­date to the fed­er­al tri­als data­base say­ing the pre­ma­ture ter­mi­na­tion fol­lowed an “in­ter­nal safe­ty as­sess­ment.”

The IV-ad­min­is­tered FLT3 ag­o­nist, dubbed GS-3583, was be­ing test­ed as a monother­a­py in 13 pa­tients with ad­vanced sol­id tu­mors. The goal of the tri­al was to find out what dose to test in a Phase II, or max­i­mum tol­er­at­ed dose.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.